By Fineline Cube 
Novo Nordisk A/S (NYSE: NVO) announced that semaglutide injection (brand name: Wegovy) has received approval from China’s National Medical Products Administration (NMPA) for a new indication: the treatment of metabolic dysfunction‑associated steatohepatitis (MASH) in non‑cirrhotic adult patients with moderate‑to‑advanced liver fibrosis (consistent with F2–F3 fibrosis). With the clearance, semaglutide becomes the first and currently only GLP‑1 receptor agonist (GLP‑1RA) approved for the treatment of MASH, extending Wegovy’s label beyond weight management into a major cardiometabolic liver disease.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | New indication approval |
| Product | Semaglutide injection (Wegovy) |
| Drug Class | GLP‑1 receptor agonist (GLP‑1RA) |
| Indication | Treatment of MASH in non‑cirrhotic adults with moderate‑to‑advanced liver fibrosis (F2–F3) |
| First‑in‑Class Status | First and currently only GLP‑1RA approved for MASH |
| Approval Date | 10 September 2026 (announcement) |
| Next Steps | Commercial rollout in China; pricing and reimbursement: Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Semaglutide, a long‑acting GLP‑1 receptor agonist administered as a subcutaneous injection under the brand Wegovy for cardiometabolic indications.
- Mechanism: GLP‑1 receptor activation improves glycemic control, reduces appetite and body weight, and exerts metabolic effects that address the drivers of steatosis, inflammation, and fibrosis progression in MASH.
- Target Population: Non‑cirrhotic adults with biopsy‑consistent moderate‑to‑advanced fibrosis (F2–F3) — the stage at which MASH carries substantial risk of progression to cirrhosis and liver‑related complications, and where therapeutic intervention is most impactful.
- Therapeutic Positioning: As the first and only approved GLP‑1RA for MASH, semaglutide establishes the incretin class as a validated treatment paradigm in metabolic liver disease.
Clinical Evidence – ESSENCE Trial (Part 1)
The approval is based on primary results from Part 1 of the ESSENCE trial, an outcomes trial of semaglutide in patients with MASH and moderate‑to‑advanced liver fibrosis, which enrolled 1,197 patients with biopsy‑confirmed MASH and F2 or F3 liver fibrosis. The study met both primary histological endpoints:
| Endpoint | Semaglutide | Placebo | Relative Benefit |
|---|---|---|---|
| MASH resolution without worsening of liver fibrosis | ≈ 63 % | ≈ 34 % | +29 ppt (≈ 1.9×) |
| Improvement in liver fibrosis without worsening of MASH | ≈ 37 % | ≈ 22 % | +15 ppt (≈ 1.7×) |
The dual‑endpoint success — resolving steatohepatitis and regressing fibrosis, each without worsening of the other — provides the histological evidence base regulators require for MASH drug approval, and supports semaglutide’s positioning as a disease‑modifying therapy rather than a weight‑loss adjunct alone. Safety and tolerability details from ESSENCE: Not disclosed in the announcement.
Market Impact & Outlook
- China MASH Burden: China carries one of the world’s largest metabolic liver disease populations, with MASH prevalence rising alongside obesity and type 2 diabetes; until now, treatment options for F2–F3 fibrosis have been limited. Patient‑number estimates: Not disclosed.
- First‑Mover Exclusivity: As the first and only GLP‑1RA approved for MASH, Wegovy enters the Chinese indication without direct incretin‑class competition, positioning Novo Nordisk ahead of rival GLP‑1 and dual‑agonist developers pursuing MASH labels.
- Label Expansion Strategy: The MASH clearance adds a second major chronic‑disease indication to Wegovy’s Chinese label alongside weight management, deepening Novo Nordisk’s cardiometabolic franchise and hospital‑channel engagement in hepatology and endocrinology.
- Global Read‑Across: ESSENCE outcomes strengthen the evidence package supporting semaglutide’s MASH positioning internationally; regulatory decisions in other regions remain subject to local agency timelines. Payer and pricing negotiations in China: Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercialization of the MASH indication for Wegovy in China, reimbursement and pricing outcomes, further regulatory filings, and clinical development expectations for semaglutide. Actual results may differ materially due to risks including market adoption, competitive entry by other MASH therapies, reimbursement negotiations, manufacturing and supply constraints, and evolving treatment guidelines.-Fineline Info & Tech